1Īdult patients with stage IV recurrent NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and no known sensitizing EGFR or ALK alterations were stratified by PD-L1 score (2 months. At the 2021 ASCO Annual Meeting, researchers reported efficacy data with at least 2 years’ follow-up from the CheckMate-9LA study. Clinical benefit was observed regardless of PD-L1 expression level and histology. In the randomized phase 3 CheckMate-9LA trial, combination use of nivolumab (NIVO) and ipilimumab (IPI) plus 2 cycles of chemotherapy significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) compared with chemotherapy alone (4 cycles) as first-line therapy for patients with advanced NSCLC. Immunotherapy Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab and Chemotherapy in First-Line Advanced NSCLC After 2 years, combination use of nivolumab and ipilimumab together with chemotherapy demonstrated durable survival and other efficacy benefits relative to chemotherapy alone in first-line patients with advanced NSCLC. We hope that the information reviewed here can be applied to clinical practice and offers valuable insights into the important progress that is being made in the care of patients with NSCLC. ![]() This material is divided into the following topic areas:Ī total of 30 data presentations from AACR 2021 and ASCO 2021 are summarized in these categories. This supplement summarizes some of the most important data from these meetings that may affect the management of patients with early-stage and metastatic non–small-cell lung cancer (NSCLC). ![]() Many annual congresses, such as the American Association for Cancer Research (AACR) Annual Meeting 2021 and the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, were conducted as virtual programs this year, enabling researchers to share information in hundreds of posters and presentations. In 2021, despite the COVID-19 pandemic, there have been many exciting developments in biomarker testing and other diagnostics, treatment approaches and targets, and other aspects of cancer care. ![]() Researchers and clinicians continue to make advances in the treatment of cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |